8-K
filed January 20, 2026, 6:59 PM ET
ticker VVOS
CIK 0001716166
other material
confidence high
sentiment neutral
materiality 0.70
Vivos Therapeutics raises $4.6M via warrant exercise and issues new warrants for 3.96M shares
Vivos Therapeutics, Inc.
- Gross proceeds of ~$4.6M from immediate cash exercise of existing warrants at reduced price of $2.34/share.
- Issued Series A (5-yr) and Series B (24-mo) warrants to purchase up to 3,964,712 shares at $2.09/share.
- Must file resale registration for new warrant shares by Feb 14, 2026; effective by Mar 16 or Apr 15 if SEC review.
- Placement agent H.C. Wainwright paid 7% cash fee and received warrants for 138,765 shares at $2.925/share.
- Until Feb 19, 2026, company restricted from issuing additional shares or filing registration statements.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Vivos Therapeutics, Inc. issued 138,765 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC.
- Security
- warrant
- Shares
- 138,765 shares of Common Stock
- Purchaser
- H.C. Wainwright & Co., LLC
Exact text from the filing
issued to Wainwright or its designees warrants to purchase 138,765 shares of Common Stock representing 7.0% of the shares of Common Stock underlying the Inducement Warrants
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Vivos Therapeutics, Inc. issued up to 1,982,356 shares of Common Stock of warrant to an institutional investor.
- Security
- warrant
- Shares
- up to 1,982,356 shares of Common Stock
- Purchaser
- an institutional investor
Exact text from the filing
a five-year, Series A Common Stock Purchase Warrant to purchase up to 1,982,356 shares of Common Stock at an exercise price of $2.09 per share
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Vivos Therapeutics, Inc. issued up to 1,982,356 shares of Common Stock of warrant to an institutional investor.
- Security
- warrant
- Shares
- up to 1,982,356 shares of Common Stock
- Purchaser
- an institutional investor
Exact text from the filing
a 24-month, Series B Common Stock Purchase Warrant to purchase up to 1,982,356 shares of Common Stock at an exercise price of $2.09 per share
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Vivos Therapeutics, Inc. entered into Warrant Inducement Letter Agreement with an institutional investor valued at The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci (effective 2026-01-15).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an institutional investor
- Value
- The Company agreed to issue warrants to purchase up to 3,964,712 shares of Common Stock at an exerci
- Effective
- 2026-01-15
Exact text from the filing
On January 15, 2026, the Company entered into a warrant inducement letter agreement with the Holder (the “ Inducement Agreement ”) pursuant to which the Holder agreed to exercise for cash the entirety of the Warrants at a reduced exercise price of $2.34 per share (with such exercise price being established for purposes of compliance with the listing rules of the Nasdaq Stock Market), resulting in gross proceeds to the Company of approximately $4.6 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.